Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 6Endocrine 3NET 1Gynecologic 1

Conditions

Neuroendocrine Tumors 110Gastro-enteropancreatic neuroendocrine tumor 19Carcinoma, Neuroendocrine 12Stomach Neoplasms 10Neoplasms 10Breast Neoplasms 10Pheochromocytoma 9Pancreatic Neoplasms 9Carcinoid Tumor 9Prostatic Neoplasms 8Paraganglioma 8Neoplasm Metastasis 8Carcinoma, Hepatocellular 8Adenoma, Islet Cell 8Thyroid Neoplasms 7Gastrointestinal Neoplasms 7Esophageal Neoplasms 7Sarcoma 6Lung Neoplasms 6Colorectal Neoplasms 6Rectal Neoplasms 5Ovarian Neoplasms 5Neuroblastoma 5Melanoma 5Liver Neoplasms 5Colonic Neoplasms 5Anus Neoplasms 5Uterine Cervical Neoplasms 4Gastrointestinal Stromal Tumors 4Cholangiocarcinoma 4

Interventions

fluorodopa F 18 1Furosemide 14-chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Parkinson Disease × NET × Clear all
NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

University of Alberta

Phase 3 Recruiting
800 enrolled
CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡